Physician profile
Cheryl L Bascom
NPI 1619073319
$4,420.66
in general payments reported to CMS, 2019-2025
29 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $210 · 2021: $294 · 2022: $264 · 2023: $714 · 2024: $920 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,167.50 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $862.09 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $392.51 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $344.53 | 2019-2024 | Livdelzi |
| Janssen Biotech, INC. | $332.43 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $159.10 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $149.49 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $125.47 | 2019-2024 | Spyglass, Exalt Model D |
| Qol Medical, LLC | $107.91 | 2023-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $106.54 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $100.70 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $74.09 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $61.32 | 2023-2025 | Wegovy |
| Olympus America INC. | $59.89 | 2021 | |
| Ferring Pharmaceuticals INC. | $46.92 | 2022-2023 | Rebyota |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.29 | 2019 | |
| Ironwood Pharmaceuticals, INC | $40.44 | 2019-2021 | |
| Madrigal Pharmaceuticals | $34.75 | 2025 | Rezdiffra |
| Shionogi INC | $33.02 | 2019 | |
| Intercept Pharmaceuticals, INC. | $29.69 | 2024-2025 | |
| Ucb, INC. | $23.39 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.64 | 2021 | |
| Kci USA, INC. | $19.04 | 2023 | Prevena |
| Lilly USA, LLC | $16.31 | 2025 | Mounjaro |
| Baxter Healthcare | $15.28 | 2022 | |
| Braintree Laboratories, INC. | $13.98 | 2019 | |
| Celgene Corporation | $13.58 | 2022 | |
| Aimmune Therapeutics, INC. | $13.58 | 2025 | Vowst |
| Vivus LLC | $10.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Bascom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.